Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

<p class="MsoNormal">Featuring perspectives from Dr Aditya Bardia and Dr Adam M Brufsky, including the following topics:</p> <ul> <li class="MsoNormal">Introduction: Antibody-drug conjugates in localized breast cancer (0:00)</li> <li class="MsoNormal">Case: A frail woman in her late 70s with ER-positive, HER2-low metastatic breast cancer (mBC) receives sacituzumab govitecan after multiple lines of therapy — Eric Fox, DO (7:46)</li> <li class="MsoNormal">Case: A woman in her early 60s with NTRK-mutant ER-negative, HER2-low recurrent mBC receives trastuzumab deruxtecan — Lai (Amber) Xu, MD, PhD (21:07)</li> <li class="MsoNormal">Case: A woman in her mid 70s with PIK3CA-mutant recurrent metastatic triple-negative breast cancer who developed a diverticular abscess on neoadjuvant chemoimmunotherapy receives sacituzumab govitecan and pembrolizumab — Alan B Astrow, MD (31:49)</li> <li class="MsoNormal">Case: A woman in her mid 60s with ER-negative, HER2-low mBC receives sacituzumab govitecan ...